#NSCLC Market

[healthcareporium]

Innovating Lung Cancer Care: Antibody-Drug Conjugates Lead the Way

The ENHERTU Effect: A Closer Look at the Dynamic Duo Daiichi Sankyo and AstraZeneca Taking on HER2-mutant NSCLC Lung cancer remains one of the most challenging and prevalent forms of cancer. Within this landscape, innovative treatments are offering new hope. One such breakthrough is the collaboration between Daiichi Sankyo and AstraZeneca, which brings forth ENHERTU, an Antibody-Drug Conjugate…

[futuretonext]

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide. 

[delveinsight12]

MET Kinase Inhibitor Market: Size, Target Population, Competitive Landscape, and Forecast to 2034

The MET kinase inhibitor market represents a significant and rapidly advancing segment of cancer therapeutics, particularly in addressing malignancies driven by MET (mesenchymal-epithelial transition factor) signaling dysregulation. These inhibitors target the MET pathway, which is implicated in tumor growth, metastasis, and treatment resistance in various cancers. Here, we delve into the market dynamics, including its size, target population, competitive environment, and future outlook to 2034.

MET Kinase Inhibitor Market Size and Growth Drivers

The MET kinase inhibitor market is forecasted to experience substantial growth through 2034, driven by advancements in oncology research and the increasing prevalence of MET-driven cancers. MET pathway dysregulation is common in cancers like non-small cell lung cancer (NSCLC), gastric cancer, and papillary renal cell carcinoma, creating significant demand for targeted therapies.

The market is buoyed by:

- Expanding therapeutic applications: Beyond cancer, MET inhibitors are being explored for fibrotic and inflammatory diseases, which could broaden their market scope.

- Rising investments in oncology: Governments and private entities are boosting funding in cancer research, accelerating drug development and commercialization.

- Improved diagnostic capabilities: Advances in precision medicine enable better identification of MET-amplified or overexpressed tumors, facilitating targeted treatment.

North America and Europe are leading markets due to robust healthcare infrastructure and innovation hubs. Meanwhile, the Asia-Pacific region is poised for rapid growth, propelled by rising healthcare spending and increased cancer awareness.

Request for a sample page report @ https://www.delveinsight.com/sample-request/met-kinase-inhibitor-market-forecast

MET Kinase Inhibitor Target Population

The primary target population for MET kinase inhibitors includes patients with cancers harboring MET alterations:

- Non-Small Cell Lung Cancer (NSCLC): MET exon 14 skipping mutations and MET amplifications are significant targets in this subset of lung cancer patients.

- Gastric Cancer: MET overexpression is a critical factor in the pathogenesis of gastric and gastroesophageal cancers.

- Renal Cell Carcinoma: MET alterations drive tumor progression in some forms of kidney cancer.

Emerging evidence suggests potential applications in other cancers, including colorectal and breast cancer, expanding the addressable patient pool.

MET Kinase Inhibitor Competitive Landscape

The MET kinase inhibitor market is highly competitive, with both established pharmaceutical giants and innovative biotech companies actively participating. The competition is characterized by diverse therapeutic approaches, including small molecules and antibody-based inhibitors.

MET Kinase Inhibitor Key Players and Therapies

1. Novartis: The company's MET inhibitor, Capmatinib (Tabrecta), is approved for MET exon 14 skipping-mutated NSCLC, setting a benchmark for others in the field.

2. Merck KGaA: Tepotinib (Tepmetko) has shown significant efficacy in treating MET-altered NSCLC, particularly in Asian markets.

3. Eli Lilly: Lilly is actively exploring the potential of MET inhibitors as part of its oncology portfolio.

4. Emerging Biotechs: Several smaller firms are developing novel MET inhibitors, including bispecific antibodies that simultaneously target MET and other pathways to overcome resistance mechanisms.

MET Kinase Inhibitor Pipeline Developments

Over 20 candidates are in various stages of development, reflecting a rich pipeline. Research is focused on improving specificity, reducing toxicity, and exploring combination therapies with immune checkpoint inhibitors and other agents.

MET Kinase Inhibitor Technological Innovations

Innovation is pivotal to the MET inhibitor market. Key advancements include:

- Combination Therapy: Co-targeting MET and other pathways, such as EGFR or ALK, to enhance efficacy and overcome resistance.

- Biomarker-Driven Approaches: Precision diagnostics are integral to identifying suitable patients, ensuring higher therapeutic success.

- Optimized Delivery Systems: Improving oral bioavailability and reducing side effects are priorities in new formulations.

Download sample report @ https://www.delveinsight.com/sample-request/met-kinase-inhibitor-market-forecast

MET Kinase Inhibitor Market Challenges

Despite its promising trajectory, the MET kinase inhibitor market faces challenges:

1. Resistance Development: Tumors often develop resistance to MET inhibitors, necessitating new-generation therapies.

2. High Costs: Expensive R&D processes and drug pricing limit accessibility, particularly in emerging markets.

3. Regulatory Hurdles: The stringent regulatory environment requires extensive clinical data for approval, prolonging time-to-market.

These challenges are being addressed through collaborative R&D, cost-sharing models, and regulatory streamlining.

MET Kinase Inhibitor Forecast to 2034

The MET kinase inhibitor market is projected to achieve multi-billion-dollar revenues by 2034, with a robust CAGR. Growth will be driven by:

- Expanded Indications: Beyond oncology, research into MET inhibitors for fibrosis and inflammatory diseases could open new markets.

- Global Access: Initiatives to improve drug affordability and access in low- and middle-income countries will play a key role in market expansion.

- Technological Advancements: Continued innovation in drug delivery and biomarker-driven treatments will enhance adoption.

North America and Europe will maintain leadership in market share, while Asia-Pacific emerges as a key growth region due to rising healthcare infrastructure and patient awareness.

The MET kinase inhibitor market represents a dynamic and transformative segment in precision oncology. With ongoing advancements in diagnostics, therapeutic efficacy, and broader clinical applications, MET inhibitors hold immense potential to redefine cancer treatment paradigms. Stakeholders—including pharmaceutical companies, healthcare providers, and policymakers—must navigate challenges while seizing opportunities to capitalize on this promising market.

For a comprehensive analysis, including detailed market forecasts and emerging trends, refer to the [DelveInsight MET Kinase Inhibitor Market Report](https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast).

[industryexperts]

(via Global Lung Cancer Therapeutics Market | Trends, Forecast 2024-2030)

The lung cancer therapeutics market in 2024 is dominated by the non-small cell lung cancer (NSCLC) type, which holds an estimated 85.3% share due to its high prevalence and the development of targeted therapies and immunotherapies. These advancements specifically target genetic mutations such as EGFR, ALK, and ROS1, providing personalized treatment options and improving patient outcomes with immune checkpoint inhibitors like pembrolizumab and nivolumab. Conversely, the small cell lung cancer (SCLC) segment is anticipated to register the fastest CAGR of 11% during the forecast period 2024-2030, driven by increasing smoking rates and greater awareness of available treatments. While traditional SCLC therapies primarily consist of chemotherapy and radiotherapy, the introduction of new treatments like immune checkpoint inhibitors is beginning to improve survival rates, leading to a surge in global demand for lung cancer therapeutics.

[medlama]

Atezolizumab Injection : A Guide to Tecentriq and Its Uses in India

In recent years, immunotherapy has emerged as a groundbreaking approach in cancer treatment, offering renewed hope for patients facing difficult-to-treat cancers. One such immunotherapy drug is Atezolizumab, marketed under the brand name Tecentriq. This drug has shown promising results in treating a variety of cancers, including lung cancer, bladder cancer, and specific forms of breast cancer. However, like many innovative treatments, the cost can be a concern, particularly in India. In this post, we will explore the atezolizumab injection price, its uses, and what patients can expect when considering Tecentriq as part of their cancer treatment plan.

Atezolizumab – Uses & Introduction

Atezolizumab is a cancer immunotherapy drug classified as a PD-L1 inhibitor. It enhances the immune system’s ability to recognize and destroy cancer cells. In normal conditions, cancer cells evade the immune system by producing a protein called PD-L1, which essentially “turns off” the body’s immune response against them. Atezolizumab blocks this PD-L1 protein, allowing the immune system to detect and attack cancer cells more effectively.

Atezolizumab injection is used to treat various cancers, including:

Non-small cell lung cancer (NSCLC)

Small cell lung cancer (SCLC)

Urothelial carcinoma (bladder cancer)

Triple-negative breast cancer (TNBC)

Hepatocellular carcinoma (liver cancer)

It is often prescribed for advanced-stage cancers or when the cancer has metastasized (spread to other parts of the body). Atezolizumab is typically administered alongside chemotherapy or other cancer treatments, depending on the type and stage of the cancer.

How Does Atezolizumab Work? The Mechanism of Action

Understanding how Atezolizumab works can provide patients with a clearer perspective on its role in cancer treatment. Under normal circumstances, the immune system attacks anything recognized as harmful, including cancer cells. However, tumors can avoid immune detection by producing PD-L1, which effectively shuts down the immune response.

Atezolizumab interrupts this process by binding to PD-L1 and preventing it from interacting with the PD-1 receptor on immune cells. This restores the immune system’s ability to recognize and fight cancer cells, allowing for a more targeted and effective treatment. As a result, many patients experience improved outcomes, particularly in advanced cancers.

Tecentriq 1200mg Injection Price in India

Like most immunotherapy drugs, the cost of Atezolizumab is significant, and it’s important to consider the Tecentriq 1200mg injection price when planning treatment. In India, the price typically ranges from ₹2.5 lakh to ₹3.5 lakh per dose, depending on the healthcare provider, location, and any applicable discounts or assistance programs.

The high cost reflects the advanced nature of the drug’s formulation and the research behind its development. For many patients, Atezolizumab requires multiple doses over a period of months, depending on the cancer type and stage, which can substantially increase the total treatment cost.

Atezolizumab Injection Price: What Influences the Cost?

Several factors contribute to the atezolizumab injection price in India:

Manufacturer: Tecentriq is produced by Roche, a global pharmaceutical leader, and the cost reflects the investment in research, clinical trials, and obtaining regulatory approvals.

Healthcare Facility: The cost can vary depending on whether treatment is administered in private hospitals, public healthcare facilities, or specialized cancer clinics.

Insurance Coverage: Patients with comprehensive insurance may have some of the costs covered, though policies can differ widely, so it’s important to confirm coverage specifics.

Number of Doses: Treatment duration and the number of doses required depend on the type of cancer and its progression, directly impacting overall costs.

Although the atezolizumab injection price can be high, it offers life-extending benefits for many cancer patients, making the investment in treatment worthwhile for eligible individuals.

 Financial Assistance and Support Options

Given the high Tecentriq 1200mg injection price, financial assistance programs are available to help patients manage treatment costs. These include:

Insurance: Health insurance providers may offer partial or full coverage for immunotherapy treatments like Atezolizumab. Check with your insurance provider to confirm coverage.

Pharmaceutical Assistance Programs: Roche offers patient support programs that can reduce the out-of-pocket costs for Tecentriq. For those in need of financial aid, Medlama can assist in connecting patients with such programs to obtain the best possible price for Atezolizumab.

Government Health Schemes: Programs like Ayushman Bharat offer affordable cancer treatment for eligible patients in India, providing further financial support.

Non-Profit Organizations: Organizations like the Indian Cancer Society and CanSupport provide financial assistance to cancer patients who cannot afford treatment costs.

Exploring these options can significantly ease the financial burden of cancer treatment.

What to Expect During Atezolizumab Treatment

Atezolizumab is administered as an IV infusion, typically every two to four weeks, depending on the patient’s specific treatment plan. Each session lasts about 30 to 60 minutes.

Common side effects include fatigue, nausea, and reduced appetite. Some patients may also experience immune-related side effects, such as inflammation in organs like the lungs, liver, or intestines. Close monitoring by a healthcare team is essential to manage these side effects and ensure treatment efficacy.

Conclusion: Balancing Cost and Treatment Effectiveness

Atezolizumab, sold under the brand name Tecentriq, represents a breakthrough in cancer treatment, offering new hope for patients with advanced or difficult-to-treat cancers. However, the atezolizumab injection price in India, ranging between ₹2.5 lakh and ₹3.5 lakh per dose, can be a significant financial concern. 

For those exploring this treatment, it’s essential to explore available financial assistance programs. Consult with your healthcare provider or pharmacy counselor at Medlama to find the best possible offers and support options, ensuring you receive the treatment without an overwhelming financial burden.

Source URL- https://medlama.com/product/tecentriq/

[tamanna31]

Future and Growth of Tissue Diagnostics Market by 2030

Tissue Diagnostics Market

The global tissue diagnostics market size was estimated at USD 5.19 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.15% from 2023 to 2030.

Tissue diagnostics remains a gold standard for cancer diagnosis as these technologies capture the anatomy of tumors. With rising incidences of cancer, the tissue diagnostics industry witnesses high demand with significant growth opportunities over the forecast period. The impact of COVID-19 on the tissue diagnostics industry has been significant. During the pandemic, there was a slowdown in routine medical procedures, including diagnostic testing, as healthcare resources were redirected toward managing the virus.

Gather more insights about the market drivers, restrains and growth of the Tissue Diagnostics Market

The pandemic led to a temporary decline in the demand for tissue diagnostics products and services. However, as the situation improved and healthcare systems adapted to the new normal, the market began to recover. The need for accurate diagnosis and monitoring of various diseases, including cancer, remained high, driving the demand for tissue diagnostics in the post-pandemic period.

Cancer incidences are increasing dramatically, which has caused a paradigm change in anatomic pathology. This, in turn, is contributing to the clinical pathology field's continued growth. Digitalization of diagnosis methods, increased use of liquid biopsy for cancer detection, and a continuous convergence of anatomical and molecular pathology. The importance of integrated bioinformatics and analyses increases as computational pathology gains momentum. Over the past two decades, the tissue diagnostics industry has changed as more advanced equipment has become available, making life easier for pathologists and physicians.

For instance, in May 2021, to increase the availability of precision medication for lung cancer, QIAGEN released its first FDA-approved tissue companion diagnostic to detect the KRAS G12C mutation in NSCLC tumors. The Rotor-Gene Q MDx instrument, a part of the modular QIAsymphony family of automation solutions, is used with the real-time qualitative PCR kit. This tool builds on QIAGEN's nine years of experience in researching and marketing KRAS CDx tests.

Globally, more than 14 million individuals are diagnosed with cancer each year, and by 2030, that figure is projected to increase to more than 21 million. Major market participants are introducing new cancer diagnosis products. For instance, Roche introduced its innovative BenchMark ULTRA PLUS system for cancer diagnostics in June 2022, enabling prompt, precise patient care. Pathologists can deliver high-quality, time-sensitive results to doctors and patients due to the BenchMark ULTRA PLUS tissue staining system's improved workflow, testing efficiency, and environmentally sustainable features.

Considering the rising worldwide cancer burden, various technologies, and improvements in tissue diagnostics (TDx) will increase pathology efficiency, which is essential for better cancer therapy and diagnosis. For example, Ibex Medical Analytics, the industry pioneer in AI-powered cancer diagnoses, and Alverno Laboratories announced a new deal in March 2023. It aims to expand the implementation of Ibex's Galen suite of Artificial Intelligence solutions to the entire Alverno network across Indiana and Illinois. The deployment comprises AI-powered solutions for cancer diagnosis across numerous tissue types and will help Alverno pathologists in providing the highest quality care for their patients.

A rise in the adoption rate of automated tissue-based diagnostic systems by research institutes enables them to diagnose tumors faster. In January 2023, MilliporeSigma announced its plans to expand its portfolio of antibodies for tissue diagnostics to help improve the classification of gliomas and other tumors in the nervous systems. Such R&D investments will ensure the market continues to grow.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

The global hematologic malignancies market size was valued at USD 67.23 billion in 2023 and is projected to grow at a CAGR of 8.0% from 2024 to 2030.

The global precision diagnostics market size was estimated at USD 15.60 billion in 2023 and is projected to grow at a CAGR of 18.4% from 2024 to 2030.

Key Companies & Market Share Insights

The tissue diagnostics market is fragmented due to the presence of several medium-to-small and large participants in the marketspace. The advent of novel diagnostic models by key players to enhance their technology portfolio has raised competitiveness in the market. For instance, in June 2022, Roche announced the launch of VENTANA DP 600 - the next-generation slide scanner. This high-capacity slide scanner provides the pathology lab with workflow flexibility and ease of use while producing stained histology slides with exceptional image quality from tissue samples. Some prominent players in the global tissue diagnostics market include:

F. Hoffmann-La Roche Ltd.

Abbott Laboratories

Thermo Fisher Scientific Inc.

Siemens

Danaher

bioMérieux SA

QIAGEN

BD

Merck KGaA

GE Healthcare

BioGenex

Cell Signaling Technology, Inc.

Bio SB

DiaGenic ASA

Agilent Technologies

Order a free sample PDF of the Tissue Diagnostics Market Intelligence Study, published by Grand View Research.

[healthcaremarketanalysis]

Exploring the Versatile Uses of Liquid Biopsies in Modern Medicine

In recent years, liquid biopsy has emerged as a groundbreaking tool in the field of medicine, offering a less invasive alternative to traditional tissue biopsies. This innovative technique, which involves the analysis of biomarkers in bodily fluids such as blood, urine, or saliva, is revolutionizing the way we diagnose, monitor, and treat various diseases. Let’s delve into the versatile uses of liquid biopsies and how they are transforming healthcare.

Download PDF Brochure

1. Cancer Detection and Diagnosis

One of the most significant uses of liquid biopsy is in the early detection and diagnosis of cancer. Traditional tissue biopsies can be invasive, painful, and sometimes risky. In contrast, liquid biopsies offer a non-invasive way to detect cancerous cells or DNA fragments (circulating tumor DNA or ctDNA) in the bloodstream. This allows for the identification of cancer at an earlier stage, often before symptoms appear, which can lead to more effective treatment options and improved patient outcomes.

2. Monitoring Treatment Response

Liquid biopsies are also invaluable in monitoring how well a patient is responding to cancer treatment. By regularly analyzing the ctDNA levels in a patient’s blood, doctors can determine whether a treatment is effectively targeting the tumor. If ctDNA levels decrease, it indicates that the treatment is working. Conversely, an increase may suggest that the cancer is not responding to the therapy, prompting a change in the treatment plan.

3. Detecting Cancer Recurrence

For cancer survivors, the fear of recurrence is ever-present. Liquid biopsy offers a way to monitor patients after treatment to detect any signs of cancer returning. By analyzing blood samples for ctDNA, doctors can identify a recurrence long before it would be detectable through imaging or other traditional methods. Early detection of recurrence allows for prompt intervention, potentially improving the chances of successful treatment.

4. Identifying Genetic Mutations

Liquid biopsy is not limited to detecting cancer alone. It can also be used to identify specific genetic mutations that may be present in a patient’s tumor. This information is crucial for personalized medicine, where treatments are tailored to the individual based on the genetic profile of their disease. For example, in cases of non-small cell lung cancer (NSCLC), liquid biopsy can detect mutations in the EGFR gene, which can guide the use of targeted therapies.

Request Sample Pages

5. Non-Cancer Applications

While liquid biopsy is most commonly associated with cancer, its applications extend beyond oncology. Researchers are exploring its use in detecting and monitoring other conditions, such as cardiovascular diseases, infectious diseases, and prenatal testing. For instance, liquid biopsy can detect fetal DNA in a pregnant woman’s blood, providing a non-invasive method for prenatal genetic testing.

6. Advancing Research and Drug Development

Liquid biopsies are also playing a pivotal role in research and drug development. Pharmaceutical companies use liquid biopsy to identify biomarkers and genetic mutations that are critical in the development of targeted therapies. This not only speeds up the drug development process but also enhances the precision of clinical trials by selecting patients who are more likely to benefit from a specific treatment.

Conclusion

The uses of liquid biopsy are vast and varied, making it a powerful tool in modern medicine. From early cancer detection to personalized treatment plans and beyond, liquid biopsy is transforming how we approach disease management and treatment. As research and technology continue to advance, the potential of liquid biopsy will only grow, offering hope for earlier diagnoses, more effective treatments, and better patient outcomes across a range of medical conditions.

Content Source:

https://www.prnewswire.com/news-releases/liquid-biopsy-market-worth-11-3-billion--marketsandmarkets-302139796.htmlhttps://www.globenewswire.com/en/news-release/2024/05/27/2888486/0/en/Liquid-Biopsy-Market-is-Expected-to-Reach-11-3-billion-MarketsandMarkets.html

[industrynewsupdates]

Tissue Diagnostics Market Business Growth, Opportunities and Forecast, 2030

The global tissue diagnostics market size was estimated at USD 5.19 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.15% from 2023 to 2030.

Tissue diagnostics remains a gold standard for cancer diagnosis as these technologies capture the anatomy of tumors. With rising incidences of cancer, the tissue diagnostics industry witnesses high demand with significant growth opportunities over the forecast period. The impact of COVID-19 on the tissue diagnostics industry has been significant. During the pandemic, there was a slowdown in routine medical procedures, including diagnostic testing, as healthcare resources were redirected toward managing the virus.

Gather more insights about the market drivers, restrains and growth of the Tissue Diagnostics Market

The pandemic led to a temporary decline in the demand for tissue diagnostics products and services. However, as the situation improved and healthcare systems adapted to the new normal, the market began to recover. The need for accurate diagnosis and monitoring of various diseases, including cancer, remained high, driving the demand for tissue diagnostics in the post-pandemic period.

Cancer incidences are increasing dramatically, which has caused a paradigm change in anatomic pathology. This, in turn, is contributing to the clinical pathology field's continued growth. Digitalization of diagnosis methods, increased use of liquid biopsy for cancer detection, and a continuous convergence of anatomical and molecular pathology. The importance of integrated bioinformatics and analyses increases as computational pathology gains momentum. Over the past two decades, the tissue diagnostics industry has changed as more advanced equipment has become available, making life easier for pathologists and physicians.

For instance, in May 2021, to increase the availability of precision medication for lung cancer, QIAGEN released its first FDA-approved tissue companion diagnostic to detect the KRAS G12C mutation in NSCLC tumors. The Rotor-Gene Q MDx instrument, a part of the modular QIAsymphony family of automation solutions, is used with the real-time qualitative PCR kit. This tool builds on QIAGEN's nine years of experience in researching and marketing KRAS CDx tests.

Globally, more than 14 million individuals are diagnosed with cancer each year, and by 2030, that figure is projected to increase to more than 21 million. Major market participants are introducing new cancer diagnosis products. For instance, Roche introduced its innovative BenchMark ULTRA PLUS system for cancer diagnostics in June 2022, enabling prompt, precise patient care. Pathologists can deliver high-quality, time-sensitive results to doctors and patients due to the BenchMark ULTRA PLUS tissue staining system's improved workflow, testing efficiency, and environmentally sustainable features.

Considering the rising worldwide cancer burden, various technologies, and improvements in tissue diagnostics (TDx) will increase pathology efficiency, which is essential for better cancer therapy and diagnosis. For example, Ibex Medical Analytics, the industry pioneer in AI-powered cancer diagnoses, and Alverno Laboratories announced a new deal in March 2023. It aims to expand the implementation of Ibex's Galen suite of Artificial Intelligence solutions to the entire Alverno network across Indiana and Illinois. The deployment comprises AI-powered solutions for cancer diagnosis across numerous tissue types and will help Alverno pathologists in providing the highest quality care for their patients.

A rise in the adoption rate of automated tissue-based diagnostic systems by research institutes enables them to diagnose tumors faster. In January 2023, MilliporeSigma announced its plans to expand its portfolio of antibodies for tissue diagnostics to help improve the classification of gliomas and other tumors in the nervous systems. Such R&D investments will ensure the market continues to grow.

Tissue Diagnostic Market Segmentation

Grand View Research has segmented the global tissue diagnostics market report based on technology, application, end-use, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunohistochemistry

o Instruments

o Slide Staining Systems

o Tissue Microarrays

o Tissue Processing Systems

o Slide Scanners

o Other Products

o Consumables

o Antibodies

o Reagents

o Kits

• In Situ Hybridization

o Instruments

o Consumables

o Software

• Primary & Special Staining

• Digital Pathology and Workflow

o Whole Slide Imaging

o Image Analysis Informatics

o Information Management System Storage & Communication

• Anatomic Pathology

o Instruments

o Microtomes & Cryostat Microtomes

o Tissue Processors

o Automatic Strainers

o Other Products

o Consumables

o Reagents & Antibodies

o Probes & Kits

o Others

Application Outlook (Revenue, USD Million, 2018 - 2030)

• Breast Cancer

• Non-small Cell Lung Cancer

• Prostate Cancer

• Gastric Cancer

• Other Cancers

End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Research Laboratories

• Pharmaceutical Organizations

• Contract Research Organizations (CROs)

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o Spain

o France

o Italy

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o South Korea

o Singapore

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global hematologic malignancies market size was valued at USD 67.23 billion in 2023 and is projected to grow at a CAGR of 8.0% from 2024 to 2030.

• The global precision diagnostics market size was estimated at USD 15.60 billion in 2023 and is projected to grow at a CAGR of 18.4% from 2024 to 2030.

Key Companies & Market Share Insights

The tissue diagnostics market is fragmented due to the presence of several medium-to-small and large participants in the marketspace. The advent of novel diagnostic models by key players to enhance their technology portfolio has raised competitiveness in the market. For instance, in June 2022, Roche announced the launch of VENTANA DP 600 - the next-generation slide scanner. This high-capacity slide scanner provides the pathology lab with workflow flexibility and ease of use while producing stained histology slides with exceptional image quality from tissue samples. Some prominent players in the global tissue diagnostics market include:

• F. Hoffmann-La Roche Ltd.

• Abbott Laboratories

• Thermo Fisher Scientific Inc.

• Siemens

• Danaher

• bioMérieux SA

• QIAGEN

• BD

• Merck KGaA

• GE Healthcare

• BioGenex

• Cell Signaling Technology, Inc.

• Bio SB

• DiaGenic ASA

• Agilent Technologies

Order a free sample PDF of the Tissue Diagnostics Market Intelligence Study, published by Grand View Research.

[delveinsight12]

Understanding c-MET Non-Small Cell Lung Cancer Market: Causes, Symptoms, Diagnosis, and Treatment Options

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 85% of all lung cancer cases. Within the realm of NSCLC, c-MET-positive tumors represent a significant subset associated with specific molecular and clinical characteristics. This article provides a detailed exploration of c-MET-positive NSCLC, including its causes, signs and symptoms, diagnostic approaches, and treatment options, drawing insights from the latest market research and developments.

c-MET, also known as hepatocyte growth factor receptor (HGFR), is a proto-oncogene that plays a crucial role in cell growth, migration, and invasion. In NSCLC, the c-MET gene can become dysregulated, leading to aberrant signaling pathways that promote tumor growth and metastasis. Overexpression or mutation of the c-MET gene has been implicated in aggressive tumor behavior and resistance to standard therapies.

c-MET-positive NSCLC often presents with distinct clinical features and may require specialized treatment approaches to effectively manage the disease. Identifying and targeting c-MET alterations is essential for optimizing therapeutic strategies and improving patient outcomes.

Causes of c-MET Non-Small Cell Lung Cancer

The exact causes of c-MET-positive NSCLC are multifaceted and involve a combination of genetic and environmental factors:

1. Genetic Mutations: Mutations or amplifications in the c-MET gene can lead to the overexpression of the c-MET protein, driving tumor growth and progression. These genetic alterations can result from inherited genetic predispositions or acquired mutations.

2. Environmental Factors: Exposure to carcinogens, such as tobacco smoke, asbestos, and environmental pollutants, is a well-established risk factor for lung cancer. These environmental factors can contribute to the development of genetic mutations and aberrant signaling pathways, including those involving c-MET.

3. Preexisting Lung Conditions: Chronic lung conditions, such as chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis, can increase the risk of developing lung cancer. These conditions may contribute to the dysregulation of c-MET signaling.

4. Family History: A family history of lung cancer or other cancers can increase the risk of developing NSCLC, including c-MET-positive tumors. Genetic predisposition and familial cancer syndromes may play a role in c-MET dysregulation.

Signs and Symptoms

The symptoms of c-MET-positive NSCLC are similar to those of other NSCLC subtypes, though the presence of c-MET alterations may influence the disease's clinical behavior. Common signs and symptoms include:

1. Persistent Cough: A chronic cough that does not improve with treatment may be an early sign of lung cancer. In c-MET-positive NSCLC, the cough may become more severe and persistent.

2. Shortness of Breath: Difficulty breathing or shortness of breath can occur as the tumor grows and obstructs the airways or lung tissue.

3. Chest Pain: Patients may experience localized chest pain or discomfort, which can be caused by the tumor's growth or invasion into surrounding tissues.

4. Hemoptysis: Coughing up blood or blood-streaked sputum may indicate advanced disease or tumor invasion.

5. Weight Loss and Fatigue: Unexplained weight loss and persistent fatigue are common systemic symptoms of cancer, including c-MET-positive NSCLC.

6. Recurrent Infections: Frequent respiratory infections or pneumonia may occur as the tumor obstructs or damages the lung tissue.

To know more about c-MET NSCLC Treatment market, visit: https://www.delveinsight.com/report-store/cmet-mnsclc-market

Diagnosis of c-MET Non-Small Cell Lung Cancer

The diagnosis of c-MET-positive NSCLC involves a combination of imaging studies, biopsy, and molecular testing:

1. Imaging Studies:

   - Chest X-Ray: A preliminary imaging test that can reveal abnormalities in the lungs, such as masses or nodules.

   - Computed Tomography (CT) Scan: Provides detailed cross-sectional images of the chest and can help identify the size, location, and extent of the tumor. CT scans are often used for staging and assessing tumor spread.

   - Positron Emission Tomography (PET) Scan: PET scans can detect areas of increased metabolic activity associated with cancer, aiding in the detection of metastases.

2. Biopsy:

   - Bronchoscopy: A procedure in which a flexible tube with a camera is inserted through the airways to obtain tissue samples from the tumor.

   - Needle Biopsy: A needle is used to extract tissue samples from the tumor, often guided by imaging techniques.

3. Molecular Testing:

   - c-MET Gene Testing: Identifies mutations or amplifications in the c-MET gene that are associated with tumor growth and progression. This testing is essential for determining the appropriate targeted therapy.

   - Next-Generation Sequencing (NGS): Provides comprehensive genetic analysis to identify various mutations and alterations in the tumor, including c-MET.

Treatment Options for c-MET Non-Small Cell Lung Cancer

Treatment for c-MET-positive NSCLC often involves a combination of standard therapies and targeted approaches to address the specific molecular characteristics of the tumor:

1. Surgery: Surgical resection is often the first-line treatment for localized NSCLC. The goal is to remove the tumor and affected lung tissue. However, surgery may not be suitable for all patients, particularly those with advanced or metastatic disease.

2. Radiation Therapy: Radiation therapy uses high-energy rays to target and destroy cancer cells. It may be used as an adjuvant treatment following surgery or as a primary treatment for inoperable tumors.

3. Chemotherapy: Systemic chemotherapy involves the use of drugs to kill cancer cells throughout the body. It is often used for advanced or metastatic NSCLC and may be combined with other treatments.

4. Targeted Therapy:

   - c-MET Inhibitors: Specific drugs targeting the c-MET pathway, such as crizotinib, cabozantinib, and tepotinib, are used to inhibit abnormal c-MET signaling and reduce tumor growth. These therapies are tailored to patients with c-MET gene mutations or amplifications.

   - Combination Therapies: Combining c-MET inhibitors with other targeted agents or immunotherapies may enhance treatment efficacy and overcome resistance.

5. Immunotherapy: Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, can help stimulate the immune system to recognize and attack cancer cells. While not specific to c-MET, these therapies may be used in conjunction with targeted treatments.

6. Clinical Trials: Participation in clinical trials may provide access to new and experimental treatments that are not yet widely available. Clinical trials are essential for advancing treatment options and improving outcomes for patients with c-MET-positive NSCLC.

Market Insights

The market for c-MET-positive NSCLC treatments reflects the growing demand for targeted therapies and advancements in personalized medicine:

- Market Size and Growth: The global market for c-MET-positive NSCLC treatments is expanding, driven by increasing prevalence, advances in molecular diagnostics, and the development of targeted therapies. Key market segments include pharmaceuticals, diagnostic tools, and personalized treatment solutions.

- Key Players: Leading companies involved in the c-MET NSCLC market include:

   - Pfizer Inc.: Known for its development of targeted therapies and involvement in the treatment of lung cancer.

   - Roche Holdings: Engaged in the development of targeted therapies and molecular diagnostics for NSCLC.

   - Novartis Pharmaceuticals: Focuses on innovative treatments and research in oncology, including c-MET-targeted therapies.

   - AstraZeneca: Contributes to research and development of targeted and combination therapies for lung cancer.

- Research and Development: Ongoing research aims to improve understanding of c-MET signaling, develop new targeted therapies, and enhance diagnostic capabilities. Innovations in drug development and molecular diagnostics are contributing to better management and treatment outcomes for patients with c-MET-positive NSCLC.

c-MET-positive NSCLC represents a significant subset of non-small cell lung cancer with distinct molecular and clinical characteristics. Understanding the causes, symptoms, and treatment options is crucial for effective management of this challenging condition. Advances in targeted therapies and molecular diagnostics offer hope for improved outcomes and personalized treatment strategies. The growing market for c-MET NSCLC treatments underscores the importance of continued research and innovation in addressing this complex and impactful form of lung cancer.

Download report @ https://www.delveinsight.com/sample-request/cmet-mnsclc-market

[priteshwemarketresearch]

Avelumab Market  Trends Analysis: Research Methodologies and Growth Opportunities until 2032

Avelumab Market Introduction:

Adhering to stringent rules, possessing substantial clinical trial evidence, and being committed to patient safety are considered indicators of quality in the Avelumab market. Manufacturers and other industry players place a great value on quality control processes to ensure the drug is uniform and effective. Furthermore, quality includes ongoing R&D efforts aimed at expanding Avelumab's therapeutic applications and exploring potential combinations with other medications to improve therapeutic outcomes.

Get a sample copy of this report:https://wemarketresearch.com/reports/request-free-sample-pdf/avelumab-market/1495

Avelumab Market Size And Forecast

The market is comprehensively evaluated for the predicted period in the Global Avelumab Market research. A review of the trends and other variables that are significantly influencing the market is included in each of the report's several segments. These elements, known as market dynamics, comprise the opportunities, obstacles, drivers, and constraints that shape the market and define how these elements affect it. The market's potential and challenges are extrinsic, while its drivers and restraints are intrinsic. A revenue forecast for the market's growth over the course of the forecast period is given by the Global Avelumab Market report.

Avelumab Market Trends:

A developing category of cancer treatment is cancer immunotherapy, which includes immune checkpoint inhibitors like avelumab. As immunotherapy shows promise in the fight against a variety of malignancies, this trend is anticipated to continue.

Broadening the Scope of Treatment Applications: Avelumab is now approved for Merkel-cell carcinoma and non-small cell lung carcinoma (NSCLC), but ongoing clinical trials are assessing its effectiveness in other cancer forms as well. The market might grow dramatically if these trials are successful.

Patient-Centered Care: Avelumab's capacity to selectively target particular immune pathways presents an opportunity for customized treatment strategies, which is consistent with the increasing emphasis on patient-centered care.

Avelumab Market Scope Of the Report Market Challenges:

Competitiveness: Rivalry: Avelumab's pricing and market share may be impacted by the existence of alternative immune checkpoint inhibitors.

High Cost: Due to the drug's high cost, some patients may find it difficult to afford or for healthcare systems to pay for avelumab.

Exorbitant Treatment Costs: Avelumab, like many cancer medications, is not cheap. This may restrict patient access, particularly in nations with constrained financial resources for healthcare. Care of Side Effects: Avelumab can have infusion responses and weariness as side effects, however they are usually well tolerated. It is imperative that more study be done on controlling these negative effects.

Safety Concerns: Like many potent medications, avelumab can have detrimental side effects. These can include immunological system issues, exhaustion, lung issues, and infusion responses. Physicians must assess each patient's dangers and potential advantages.

Companies Covered: Avelumab Market:

Merck

Pfizer

Others

Global Avelumab Market Segmentation:

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Avelumab market is projected to growth factors:

Increasing Cancer Rates: An older population, lifestyle choices, and more screening are all contributing contributors to the rising incidence of cancer worldwide. As a result, there is a greater chance that patients will benefit from Avelumab.

Expanding Use of Immunotherapy: The use of Avelumab in immunotherapy is one of the fastest-growing segments of cancer treatment. Avelumab may see an increase in demand as medical professionals and patients become more aware of the possible advantages of immunotherapy.

Extending Treatment Uses: Avelumab's potential application for treating other cancer types is being researched. A larger market for Avelumab would result from additional applications being approved.

Reasons Why You Should Buy This Report:

To gain an in-depth understanding of Avelumab Market

To obtain research-based business decisions and add weight to presentations and marketing strategies

To gain competitive knowledge of leading Avelumab Market players

It gives pin point investigation of changing rivalry elements and keeps you in front of contenders.

It helps in settling on educated business choices by having total bits of knowledge of market and by making inside and out investigation of market sections.

Avelumab Market Conclusion :

Riding the Immunotherapy Wave: The market gains from the increasing acceptance of cancer immunotherapy, a major driver of which is Avelumab. Given that immunotherapy is effective against a variety of malignancies, this trend is probably here to stay.

Broadening the Spectrum of Treatment: There is a great deal of room for market expansion from the ongoing clinical trials examining Avelumab's application in novel cancer kinds. The application and patient base could be greatly expanded if these trials are successful. Opening Up New Treatment Options: Avelumab's usage in experimental cancer types is being studied in ongoing clinical trials, which could lead to significant market expansion. If these trials are successful, the application and patient base could be further expanded. Regulatory Approvals: Avelumab's sales and market reach may be greatly impacted by the extension of its regulatory approvals into new indications or geographical areas.

Market Competition: #Avelumab's pricing and market share may be impacted by rival immunotherapies, conventional cancer treatments, and the introduction of biosimilars.

Contact Us: https://wemarketresearch.com/

[retevmocapsule]

Retevmo Available Worldwide

Retevmo (selpercatinib) is a targeted therapy approved for treating specific types of cancers, including non-small cell lung cancer, medullary thyroid cancer, and other thyroid cancers. If you are looking to get the best Retevmo price in India, Indian Pharma Network (IPN) is your reliable source. IPN specializes in providing access to high-quality medications at competitive prices. With our extensive network and commitment to patient care, IPN ensures that you receive genuine Retevmo promptly and affordably. We assist in navigating the complexities of pharmaceutical procurement, ensuring you get the best possible deal. For the most competitive price and trustworthy service, Indian pharma network to manage your medication needs effectively and affordably, ensuring uninterrupted access to essential cancer treatments.

Retevmo (selpercatinib) 80 mg capsules are a breakthrough medication used for the treatment of certain cancers. Retevmo 80 mg capsule price in India can vary, but obtaining it at the most reasonable cost is essential. Indian Pharma Network (IPN) specializes in helping patients access Retevmo 80 mg capsules through legal and reliable channels. If Retevmo is not available or not approved in your home country, IPN can assist in procuring this critical therapeutic drug. Our extensive network ensures you receive authentic products, helping manage your treatment effectively. By choosing IPN, you benefit from our expertise in navigating the complexities of international pharmaceutical regulations, ensuring timely and cost-effective access to Retevmo.

Looking for the best price for Retevmo 40 mg capsules in India?

Indian Pharma Network (IPN) has you covered. Retevmo (selpercatinib) is a medication used in the treatment of certain types of non-small cell lung cancer (NSCLC), medullary thyroid cancer, and other tumors with RET gene alterations. At IPN, we understand the importance of accessing high-quality medicinal products at an affordable price. We offer the most competitive Retevmo 40 mg capsule price in India, ensuring you receive the best value for your healthcare needs. Our dedicated team ensures a seamless purchasing experience, providing prompt service and reliable delivery. Trust Indian Pharma Network (IPN) for your pharmaceutical needs and benefit from our commitment to affordability and quality.

Retevmo (selpercatinib) is a targeted therapy used to treat certain types of cancers with specific genetic mutations, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other types of thyroid cancers. Retevmo in India is not yet approved, but the Indian Pharma Network (IPN) can assist you in accessing this essential drug at the most reasonable price. Although it’s not yet available in the Indian market, IPN leverages its extensive network to procure and deliver the drug, ensuring patients receive timely and affordable treatment. IPN's commitment to patient care and affordability makes it a reliable partner for those in need of life-saving medications.

[bhushans]

Meeting the Needs of a Growing Population: The Evolving Global Liquid Biopsy Market

The global liquid biopsy market is positioned for rapid expansion, with an estimated revenue of USD 1,538.3 million in 2023. According to insights from healthcare domain experts, providers in the liquid biopsy sector can anticipate a robust Compound Annual Growth Rate (CAGR) of 21.7% through 2033. By the end of the forecast period, the market is projected to achieve a valuation of USD 10,938.6 million, reflecting significant growth opportunities within the healthcare industry.

Liquid biopsy, a non-invasive diagnostic technique that detects biomarkers and genetic material in bodily fluids, is revolutionizing cancer diagnosis, monitoring, and treatment. This innovative approach offers several advantages over traditional tissue biopsy, including real-time monitoring, early detection of treatment response or resistance, and the ability to capture tumor heterogeneity

Tumor tissue is currently the gold standard for determining the kind and stage of cancer. Important players are attempting to reduce the current obstacles to its utilization in order to increase its potential applications in the future. The feasibility of liquid biopsy techniques for identifying cancer patients’ genetic profiles has also been shown by a number of research. The studies carefully take into account the reactions in order to track the course of treatment and identify any early warning symptoms of therapeutic resistance.

Request Your Detailed Report Sample With Your Work Email : https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

Liquid biopsies have become more common in recent years due to the desire for more personalized treatment options. Since liquid biopsy is widely available and reasonably priced in many labs, particularly in developing countries, its use is growing in popularity. For instance, several labs offer liquid biopsy tests.

“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.

Key Takeaways from the Liquid Biopsy Market Report

The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.

The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.

In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.

In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.

CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.

By sample type, blood sample type holds prominence in the liquid biopsy market.

Key Developments by Liquid Biopsy Market Players

QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.

Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.

Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).

Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.

Key Companies Profiled:

BIOCEPT, INC.

Qiagen N.V.

Trovagene, Inc

Janssen Global Services, LLC

MDxHealth SA

Natera, Inc

F. Hoffmann-La Roche Ltd

Silicon Biosystems

Pathway Genomics Corporation

Sysmex Corporation

Others

Key Segments Profiled in the Liquid Biopsy Industry Survey:

By Biomarker Type:

CTCs (Circulating Tumour Cells)

ctNA (Circulating tumor Nucleic Acids)

Exosomes

By Sample Type:

Blood Liquid Biopsy

Urine Liquid Biopsy

Other (Plasma, Saliva, CSF) Liquid Biopsy

By Application Type:

Liquid Biopsy for Lung Cancer

Liquid Biopsy for Gastrointestinal Cancer

Liquid Biopsy for Prostate Cancer

Liquid Biopsy for Breast Cancer

Liquid Biopsy for Colorectal Cancer

Liquid Biopsy for Leukemia

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

Japan

Middle East and Africa

[fairfield-research]

Oncology Drugs Market Growth, Trends, Size, Share, Demand And Top Growing Companies 2031

In a landscape where the battle against cancer rages on, advancements in healthcare systems, public health measures, and novel pharmaceutical therapies have ushered in a new era of hope. According to the National Cancer Institute, the United States saw an estimated 1,806,590 new cancer cases and approximately 606,520 deaths due to the disease in 2020. However, over the past five decades, cancer survival rates have soared from 50% in 1970 to an impressive 70%, thanks to a trifecta of progress.

For more information: https://www.fairfieldmarketresearch.com/report/oncology-drugs-market

Unprecedented Growth Trajectory: The global oncology therapy sales are forecasted to surpass US$ 300 billion by 2026, with oncology contributing 21.7% to total pharmaceutical sales. Fueling this growth are the top 10 pharmaceutical companies, which have declared oncology as their key focus area, driving multibillion-dollar M&A deals and strategic collaborations. Pfizer's acquisition of Array BioPharma for US$11 billion in 2019 and AbbVie's strategic partnership with Genmab for a bispecific antibody development deal worth US$3 billion are testament to this focus.

Diverse Indications Drive Demand: While oncology represents over 20 different indications, a significant portion of revenue stems from just five of them: breast cancer, multiple myeloma, non-small-cell lung carcinoma (NSCLC), prostate cancer, and non-Hodgkin's lymphoma (NHL), which collectively accounted for approximately 65% of the market in 2020. Moreover, with breast, lung, and colorectal cancers expected to collectively account for ~50% of all new cancer diagnoses by 2026, the demand for innovative therapies continues to surge.

Disruptive Trends Reshape Landscape: Innovation in oncology is accelerating, with disruptive technologies such as cell therapy, RNA therapy, viral vectors, and stem cell therapy gaining traction. Recent approvals of CAR-T cell therapies like Kymriah and Yescarta for acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) respectively signal a new frontier in cancer treatment. Precision medicine is also driving progress, with over 160 oncology biomarkers approved by 2019, paving the way for more targeted and effective therapies.

Impact of COVID-19: Despite remarkable progress, oncology has been among the worst-hit therapeutic areas amid the COVID-19 pandemic. Decreased demand for physician-administered products, disruptions in cancer screenings, and a decline in new clinical trials have posed significant challenges. However, the industry remains resilient, adapting to the evolving landscape and ensuring continued innovation.

Immuno-Oncology Leads the Way: Immuno-oncology sales are expected to soar to ~US$ 95 billion by 2026, with agents and protein kinase inhibitors comprising ~65% of sales. With over 550 active cell- and gene-therapy agents under clinical development, the future of cancer treatment looks promising. Investments in combination studies and the exploration of new mechanisms underscore the industry's commitment to advancing immuno-oncology therapies.Roche and Keytruda: Leading the Charge: In a highly concentrated market where the top 10 companies capture over 75% of the market value, F. Hoffmann-La Roche AG (Roche) and Merck & Co. stand out as leaders. While Roche maintains its global leadership position, Merck's Keytruda is poised to become the world's top-selling oncology